Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (1): 96-99.doi: 10.3969/j.issn.1000-6621.2021.01.018
• Review Articles • Previous Articles Next Articles
Received:
2020-09-14
Online:
2021-01-10
Published:
2021-01-12
Contact:
CHU Nai-hui
E-mail:dongchu1994@sina.com
DUAN Hong-fei, CHU Nai-hui. Research progress of clinical endpoints in clinical trials of novel antituberculosis agents[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 96-99. doi: 10.3969/j.issn.1000-6621.2021.01.018
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.01.018
[1] |
Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis, 2013,13(4):362-372. doi: 10.1016/S1473-3099(13)70034-3.
doi: 10.1016/S1473-3099(13)70034-3 URL |
[2] |
Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet, 2010,375(9729):1920-1937. doi: 10.1016/S0140-6736(10)60359-5.
doi: 10.1016/S0140-6736(10)60359-5 URL pmid: 20488517 |
[3] |
Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis, 2016,16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0.
doi: 10.1016/S1473-3099(16)00070-0 URL pmid: 27036358 |
[4] |
Perrin FMR, Lipman MCI, McHugh TD, et al. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis, 2007,7(7):481-490. doi: 10.1016/S1473-3099(07)70112-3.
doi: 10.1016/S1473-3099(07)70112-3 URL |
[5] |
Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis, 1980,121(6):939-949. doi: 10.1164/arrd.1980.121.6.939.
doi: 10.1164/arrd.1980.121.6.939 URL pmid: 6774638 |
[6] |
Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother, 2008,52(8):2831-2835. doi: 10.1128/AAC.01204-07.
doi: 10.1128/AAC.01204-07 URL pmid: 18505852 |
[7] |
Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis, 1993,147(4), 1062-1063. doi: 10.1164/ajrccm/147.4.1062.
doi: 10.1164/ajrccm/147.4.1062 URL pmid: 8466107 |
[8] |
Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med, 2014,371(17):1577-1587. doi: 10.1056/NEJMoa1407426.
doi: 10.1056/NEJMoa1407426 URL pmid: 25196020 |
[9] |
Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis, 2010,10(6):387-394. doi: 10.1016/S1473-3099(10)70071-2.
doi: 10.1016/S1473-3099(10)70071-2 URL |
[10] |
Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort stu-dies. Lancet Respir Med, 2015,3(3):201-209. doi: 10.1016/S2213-2600(15)00036-3.
doi: 10.1016/S2213-2600(15)00036-3 URL |
[11] |
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014,371(8):723-732. doi: 10.1056/NEJMoa1313865.
doi: 10.1056/NEJMoa1313865 URL pmid: 25140958 |
[12] |
Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012,366(23):2151-2160. doi: 10.1056/NEJMoa1112433.
doi: 10.1056/NEJMoa1112433 URL pmid: 22670901 |
[13] |
Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med, 2012,367(16):1508-1518. doi: 10.1056/NEJMoa1201964.
doi: 10.1056/NEJMoa1201964 URL pmid: 23075177 |
[14] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020,382(10):893-902. doi: 10.1056/NEJMoa1901814.
doi: 10.1056/NEJMoa1901814 URL pmid: 32130813 |
[15] |
Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis, 2014,58(12):1676-1683. doi: 10.1093/cid/ciu186.
doi: 10.1093/cid/ciu186 URL |
[16] |
Nsofor CA, Jiang Q, Wu J, et al. Transmission is a Noticeable Cause of Resistance Among Treated Tuberculosis Patients in Shanghai, China. Sci Rep, 2017,7(1):7691. doi: 10.1038/s41598-017-08061-3.
doi: 10.1038/s41598-017-08061-3 URL pmid: 28794425 |
[17] |
Li X, Zhang Y, Shen X, et al. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis, 2007,195(6):864-869. doi: 10.1086/511985.
doi: 10.1086/511985 URL pmid: 17299717 |
[18] |
Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med, 2019,380(13):1201-1213. doi: 10.1056/NEJMoa1811867.
doi: 10.1056/NEJMoa1811867 URL pmid: 30865791 |
[19] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009,360(23):2397-2405. doi: 10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427 URL pmid: 19494215 |
[20] |
von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med, 2019,7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0.
doi: 10.1016/S2213-2600(18)30426-0 URL pmid: 30630778 |
[21] |
Chen RY, Dodd LE, Lee M, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resis-tant tuberculosis. Sci Transl Med, 2014,6(265):265ra166. doi: 10.1126/scitranslmed.3009501.
doi: 10.1126/scitranslmed.3009501 URL pmid: 25473034 |
[22] |
Coleman MT, Chen RY, Lee M, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med, 2014,6(265):265ra167. doi: 10.1126/scitranslmed.3009500.
doi: 10.1126/scitranslmed.3009500 URL pmid: 25473035 |
[23] |
Coleman MT, Maiello P, Tomko J, et al. Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun, 2014,82(6):2400-2404. doi: 10.1128/IAI.01599-13.
doi: 10.1128/IAI.01599-13 URL |
[24] |
Lin PL, Coleman T, Carney JPJ, et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother, 2013,57(9):4237-4244. doi: 10.1128/AAC.00277-13.
doi: 10.1128/AAC.00277-13 URL pmid: 23796926 |
[25] |
Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med, 2013,1(6):462-470. doi: 10.1016/S2213-2600(13)70119-X.
doi: 10.1016/S2213-2600(13)70119-X URL pmid: 24429244 |
[26] |
Friedrich SO, Venter A, Kayigire XA, et al. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol, 2011,49(8):2827-2831. doi: 10.1128/JCM.00138-11.
doi: 10.1128/JCM.00138-11 URL |
[27] |
Shenai S, Ronacher K, Malherbe S, et al. Bacterial loads measured by the Xpert MTB/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB. PLoS One, 2016,11(8):e0160062. doi: 10.1371/journal.pone.0160062.
doi: 10.1371/journal.pone.0160062 URL pmid: 27508390 |
[28] |
Malherbe ST, Shenai S, Ronacher K, et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med, 2016,22(10):1094-1100. doi: 10.1038/nm.4177.
doi: 10.1038/nm.4177 URL pmid: 27595324 |
[1] | CAO Xin-yu, XUE Miao, WEN Yan, LIU Li. Research progress on susceptibility genes of anti-tuberculous drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 190-193. |
[2] | RUAN Hong-yun, LI Qi, CHEN Xiao-you, DUAN Hong-fei, GUO Chao, CAO Min, LIANG Qing-tao, WANG Zhi-ru, YANG Yang, SUN Gui-xin, LI Hua, DENG Ling, SHAO Ling-ling, XING Wei-xiang, ZHANG Yun, YANG Xin-ting. Dynamic changes of lung function and hormone-assisted therapy in patients with tuberculous pleurisy [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 58-65. |
[3] | ZHANG Jing, CHEN Xi, WANG Bin, FU Lei, LU Yu, CHEN Xiao-you. Establishment of modified propidium monoazide (PMAxx)-quantitative PCR assay and its application for identification of antituberculosis drug activity [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 472-480. |
[4] | GAO Tian-hui,SHU Wei,GAO Jing-tao,LU Yu,LI Qi. Analysis of clarithromycin resistance and its influencing factors in 254 patients with drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 259-265. |
[5] | CHEN Hao,WU Nan-nan,HU Wen-hui,YANG Zhong-jin. Research progress of new targets for antituberculosis agents [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 286-292. |
[6] | WANG Jing,ZHANG Meng,HE Jian-qing. Clostridium difficile-associated diarrhea caused by anti-tuberculosis drugs: a case report and literature review [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 293-296. |
[7] | QIU Lei,ZHANG Shao-yan,GUO Xiao-yan,FU Ji-you,TIAN Li-ming,ZHANG Hui-yong,LU Zhen-hui. Clinical value of chemotherapy regimen and Qinbudan tablet on the retreatment of retreated smear-positive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 108-114. |
[8] | WANG Xue-di,JIANG Feng,DAI Qian-lan,WANG Jing,WANG Dong-mei.. Comparative analysis on drug-induced liver injury of the combination of traditional Chinese and Western medicine and single Western medicine in tuberculosis treatment (Literature review 2000-2019) [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 126-132. |
[9] | LI Meng, LU Li-ping, JIANG Qi, HONG Jian-jun, GAO Qian, YANG Chong-guang, GUO Xiao-qin. Analysis of the types and expense of therapeutic drugs for pulmonary tuberculosis in Songjiang District of Shanghai [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1329-1332. |
[10] | TANG Liang, BAO Yu-cheng, ZHANG Wen-long. Effects of anti-tubercular agents on intestinal flora and its influence on the organism [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1333-1338. |
[11] | Xi CHEN,Zhong-quan LIU,Bin WANG,Hui ZHU,Lei FU,Yuan-yuan LI,Yu LU. Evaluation of antituberculosis activities of 14 antituberculosis drugs in macrophage [J]. Chinese Journal of Antituberculosis, 2019, 41(9): 993-998. |
[12] | Board of Chinese Journal of Antituberculosis Editorial. Expert consensus on the solutions of drug side effects during the treatment of drug resistance tuberculosis [J]. Chinese Journal of Antituberculosis, 2019, 41(6): 591-603. |
[13] | Guo-fang DENG,Pei-ze ZHANG,Min YANG,Liang FU. Current knowledge and future prospects on the treatment of multidrug-resistant tuberculosis with second-line injectable agents [J]. Chinese Journal of Antituberculosis, 2019, 41(6): 604-608. |
[14] | Jiao-jie ZHAO,Yu LU. Research and progress of PK/PD for anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2019, 41(6): 700-704. |
[15] | Cun-bing GUO,Hui LI,Shu-lan ZHENG. Treatment effect of Shenqi Eleven Granules on leuccytopenia caused by antituberculosis drugs [J]. Chinese Journal of Antituberculosis, 2018, 40(3): 274-279. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||